Recently, cetuximab (an anti‐estimated glomerular filtration rate (EGFR) antibody) has been reported to enhance therapeutic effect of immunotherapy by inducing an EGFR‐specific T‐cell response and PD‐L1 immune checkpoint expression in CRC.[7] The combination of PD‐1 inhibitor with the FOLFOX regimen (5‐fluorouracil, folinic acid, and oxaliplatin) was also shown to enhance anticancer immune response in CRC by increasing expression of PD‐L1 and CD8+ T‐cell infiltration.[8] However, little is known about the mechanism of PD‐L1 regulation in CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.